Prestige Consumer Healthcare Inc (PBH) valuation
Prestige Consumer Healthcare P/E ratio history
Prestige Consumer Healthcare trades at 13.7 times its earnings over the last twelve months and 10.4 times the earnings analysts expect over the next twelve. At its last 8 fiscal year ends its P/E ranged from 5.3 (year to Mar 2018) to 42.7 (year to Mar 2017), with a median of 14.4.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Mar 31, 2026 | $59.27 | $3.91 | 15.2 | 12.8 |
| Mar 31, 2025 | $85.97 | $4.29 | 20.0 | 18.2 |
| Mar 31, 2024 | $72.56 | $4.17 | 17.4 | — |
| Mar 31, 2023 | $62.63 | -$1.65 | n/m | — |
| Mar 31, 2022 | $52.94 | $4.04 | 13.1 | 12.7 |
| Mar 31, 2021 | $44.08 | $3.25 | 13.6 | — |
| Mar 31, 2020 | $36.68 | $2.78 | 13.2 | — |
| Mar 31, 2019 | $29.91 | -$0.71 | n/m | — |
| Mar 31, 2018 | $33.72 | $6.33 | 5.3 | — |
| Mar 31, 2017 | $55.56 | $1.30 | 42.7 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Prestige Consumer Healthcare valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Prestige Consumer HealthcarePBH | $2.32B | 13.7 | 10.4 | 2.1 |
| BiohavenBHVN | $2.32B | — | — | — |
| Addus HomecareADUS | $2.34B | 22.0 | 17.2 | 1.6 |
| Clover Health Investments Corp ClaCLOV | $2.35B | — | 30.8 | 1.0 |
| Arcus BiosciencesRCUS | $2.29B | — | — | 19.6 |
| ProgynyPGNY | $2.29B | 31.7 | 13.3 | 1.7 |
| Celldex TherapeuticsCLDX | $2.36B | — | — | — |
| Transmedics GroupTMDX | $2.28B | 17.1 | 35.1 | 3.4 |
| Harmony Biosciences HldgHRMY | $2.24B | 12.6 | 6.3 | 2.3 |
| Peer median | 19.5 | 17.2 | 2.0 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: PBH financials · PBH returns
No forecast, no recommendation. This page describes Prestige Consumer Healthcare Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.